Hepatitis B Virus and 2 β-Microglobulin Concentration in Individuals Living with Human Immune Deficiency Virus in South West Nigeria

Authors

  • Lawrence Okoror Federal University, Oye-Ekiti

DOI:

https://doi.org/10.3823/1825

Keywords:

2βMicroglobulin, Hepatitis B virus, HIV, ELISA, Co-infection, Mono-infection

Abstract

Introduction

Hepatitis B virus (HBV) is a major health concern with people leaving with HIV/AIDS. However, not much have associated HBV with increase in 2β-microglobulin (2βM) concentration in people living with HIV/AIDS in sub-saharan Africa though is a tumor marker.

Materials and Methods

Blood sample (n=435) were collected from individuals attending various HIV screening centres in South west Nigeria after the exclusion of individuals testing positive to tuberculosis, Hepatitis C virus (HCV), Human papilloma virus (HPV), (all tested by ELISA technique) typhoid and malaria. Of the 435 individuals selected for the study, 110 were positive for HIV alone, 217 for HIV and HBV while 108 were mono-infected with HBV. All individuals were tested for 2MG using the quantitative ELISA technique.

Results

There was a significant increase in 2MG concentration among those infected with HIV and HBV as opposed to the low levels in mono-infected individuals when compared to the normal concentration of 2βM in healthy individuals.   

Discussion

The elevated level of 2βM in HIV coinfection with HBV as compared to the mono-infected individuals and normal concentration, is indicative of the fact that infection with HBV in HIV infected individuals may have caused the elevated 2βM in the co-infected individuals. This go to confirm that the risk of developing hepatocellular carcinoma and cirrhosis as well as other related diseases is higher in co-infected individuals. Thereby confirming that HBV is a risk factor to carcinoma in people living with HIV. 

Author Biography

Lawrence Okoror, Federal University, Oye-Ekiti

Microbiology, Professor

References

Jaroszewicz J, Riberger T, Meyer-Olson D, Mauss S, Vogel M, Ingiliz P, Payer BA, Stoll M, Manss MP, Schmidt RE, Flisiak R, Wedemeyer H, Peck-Radosavijevic M, Rockstroh J and Cornberg M. Hepatitis B surface antigen concentration in patients with HIV/HBV co-infection. PLO one 2012, 7 (8) e43143; 1-7.

European Association for the study of Liver EASL, Clinical Practice Guidelines, management of chronic hepatitis B. J of hepatol 2012, 57; 157-185.

Cornberg M, Jaroszewicz J, Manss MP, Wedemeyer H. Treatment of chronic hepatitis B. Minerva Gastroenterol. Dietol 2010, 56; 451-465.

Rheeder P, Nel L, Meeuwes F, Van SM and Meyer PWA. Beta-2 microglobulin as a predictor of peripheral arterial disease in diabetes: the effect of estimated glomerular filtration. JEMDSA 2012, 17(3):141-144

Elefsiniotis IS, Scarmeas N, Glynou I, Pantazis KD, Kada H, Mavrogiannis C. Serum beta 2-microglobulin levels in hepatitis B e antigen-negative chronic hepatitis B patients under long term lamivudine monotherapy: Relationship with virological breakthrough. Can J Gastroenterol. 2004, 18(5): 307-313.

Akdogan M, Senturk H, Mert A, Tabak F and Ozbay G. Acute exacerbation during interferon alfa treatment of chronic hepatitis hepatitis B; frequency and relation to serum β-2 microglobulin levels. J. Gastroenterol. 2003, 38; 464-470

Wanch A, Dong Y, Sethi S, Myneedu VP, Nadas A, Liu Z, Belisle J and Laal S. Biomarkers for Clinical and Incipient Tuberculosis: Performance in a TB-Endemic Country. PLO One 2008, 3 (4) DOI: 10.1371/journal.pone.0002071

Garcia-Garcia JA, Mira JA, Fernà ndez-Rivera J, Ramos AJ, Vargas J, Macias J and Pineda JA Influence of hepatitis C virus coinfection on failure of HIV-infected patients receiving highly active antiretroviral therapy to achieve normal serum β2microglobulin levels. Euro. J of Clin Microbiol and Infect. Dis. 2003, 22 (3), 194-196.

Bello M, Caridad M, Rodriguez LA, Sariego S, Verdasquera D, Vincent M, GutiÄ—rrez A and SÃ nchez M. Occult hepatitis B in Cuban HIV patients. Medicc Rev. 2001, 13 (2); 32-37.

Lukhwareni A, Burnett RJ, Selabe SG, Mzilleni MO and Mphahlele MJ. Increased detection of HBV DNA in HBsAg-antigen positive and HBsAg-negative South AfricanHIV/AIDS patients enrolling for highly active antiretroviral therapy at a tertiary hospital. J. of Med. Virol. 2009, 81 (3); 406-12.

Fabris P, Blasin MR, Giordani MT, Bernado L, Menini V,Carloto A et al. Impact of occult HBV infection in HIV/HCV coinfected patients. HBV-DNA detection in liver specimens and in serum samples. Curr. HIV Res. 2008, 6 (2): 173-9.

Burnett RJ, François G, Kow MC, Laroux-Roels G, Meheus A, Hoosen AA et al. Hepatitis B virus and Human Immune Deficiency co-infection in sub-Saharan Africa. A call for further investigation. Liver int. 2005, 25 (2): 201-13.

Modi AA and Field JJ. Viral hepatitis and HIV in Africa. AIDS Rev. 2007, (1): 25-39.

Mphahelele MJ. Impact of HIV co-infection on hepatitis B prevention and control. A view from sub-Saharan Africa. SAJEI 2008, 23 (1) 14-8.

Fabris P, Blasin MP, Giordani MT, Berando L, Menini V, Carloto A et al. (2008) Impact of occult HBV infection in HIV/HCV co-infected patients. HBV-DNA detection in liver specimens and serum samples. Curr. HIV Res. 2008, 6 (2):173-9.

Torbensen M, Thomas DL. Occult hepatitis B infection. Lancet infect. Dis. 2002, 2 (8) 479-86.

Muriuki BM, Gicheru MM, Wachira D, Nyamache AK and Khamad SA. Prevalence of hepatitis B and C viral co-infections among HIV1 infected individuals in Nairobi, Kenya. BMC Res. Notes 2013, 6:363. doi:10.1186/1756-0500-6-363.

Akyala IA, Obande G, Ishaleku D. Seroprevalence of hepatitis B and C co-infection among cohort seropositive HIV patients accessing healthcare in Nasarawa state, North Central Nigeria. Brit. J. of Psyco. Res. 2013, 1 (1) 15-24.

Amodio P, Gatta A, and Ruol A. Beta 2-microglobulin concentration in plasma and production in liver cirrhosis. J. Clin. Chem. Clin. Biochem. 1984, 22, 147-151.

Akdogan M, Senturk H, Mert A, Tabak F and Ozbay G. Acute exacerbation during interferon alpha treatment of chronic hepatitis B: frequency and relation to serum β 2-microglobulin levels. J. Gastroenterol. 2003, 38, 465-470.

Yegane S, Revanli M and Taneli F. The role of β 2-microglobulin levels in monitoring chronic hepatitis B. Tohoku J. Exp. Med. 2004, 203, 53-57.

Hofmann B, Wang Yx, Cumberland Wg, Detels R, Bozorgmehri M. Serum beta 2 microglobulin level increases in HIV infection: relation to seroconversion, CD4 T-cell fall and prognosis. AIDS. 1990, 4(3):207-14.

Wanchu A, Arora S, Bhatnagar A, Sud A, Bambery P, Singh S. Beta2 microglobulin as a surrogate marker for HIV infection: good correlation with CD4 counts. Indian J Pathol Microbiol. 2004, 47(2):298-301

Downloads

Published

2015-09-16

Issue

Vol. 8 (2015)

Section

Infectious Diseases

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).

 

Â